These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 20524096)

  • 1. Comparing angiotensin II receptor blockers on benefits beyond blood pressure.
    Siragy HM
    Adv Ther; 2010 May; 27(5):257-84. PubMed ID: 20524096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative assessment of angiotensin receptor blockers in different clinical settings.
    Verdecchia P; Angeli F; Repaci S; Mazzotta G; Gentile G; Reboldi G
    Vasc Health Risk Manag; 2009; 5():939-48. PubMed ID: 19997575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Angiotensin receptor blockers in cardiovascular disease.
    Maggioni AP
    Cardiovasc Drugs Ther; 2006 Aug; 20(4):295-308. PubMed ID: 16915347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk.
    Farsang C
    Vasc Health Risk Manag; 2011; 7():605-22. PubMed ID: 22102784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.
    Parvanova A; Chiurchiu C; Ruggenenti P; Remuzzi G
    Expert Opin Pharmacother; 2005 Sep; 6(11):1931-42. PubMed ID: 16144512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
    Neldam S
    Future Cardiol; 2010 Jan; 6(1):129-35. PubMed ID: 20014992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal protection with angiotensin receptor blockers: where do we stand.
    Schmieder RE; Ruilope LM; Barnett AH
    J Nephrol; 2011; 24(5):569-80. PubMed ID: 21404225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects.
    Silverstein RL; Fenves AZ; Ram CV
    Postgrad Med; 2004 Aug; 116(2):31-8, 41. PubMed ID: 15323152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
    Ferrario CM
    Life Sci; 2010 Feb; 86(9-10):289-99. PubMed ID: 19958778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The management of hypertension with angiotensin receptor blockers in special populations.
    Ferdinand KC; Taylor C
    Clin Cornerstone; 2009; 9 Suppl 3():S5-17. PubMed ID: 19409356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can the renin-angiotensin system protect against stroke? A focus on angiotensin II receptor blockers.
    Epstein BJ; Gums JG
    Pharmacotherapy; 2005 Apr; 25(4):531-9. PubMed ID: 15977915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.
    Meredith PA
    Curr Med Res Opin; 2007 Jul; 23(7):1693-705. PubMed ID: 17588300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L
    Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.